Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intranasal Glulisine in Mild-Moderate Alzheimer's Disease
NCT01436045Phase 2
Key facts
- Status
- Completed
- Start
- Sep 2011
- Primary completion
- Jun 2013
- Countries
- 1
- Sponsor
- HealthPartners Institute
- Modality
- Peptides
- Drugs
- insulin glulisine
- Conditions
- Alzheimer's disease (AD)
01
Overview
Phase 2, randomised, double-blind trial of insulin glulisine in Alzheimer's disease (AD) (2 arms), sponsored by HealthPartners Institute. Primary endpoints: Cognitive Performance, Trail Making Test Part B - Seconds and 1 more. Started Sep 2011; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Insulin glulisine
Intranasal insulin glulisine 20 IU
Saline
Intranasal saline placebo
03
Who it enrols
Patients aged 65-85 with probable mild-moderate Alzheimer's Disease (MMSE 18-26, CDR 1-2) on stable AChEI or memantine. Excludes diabetes, heavy smoking, and other significant CNS or psychiatric disorders.
04
Endpoints
Primary
Cognitive Performance
Trail Making Test Part B - Seconds
Trail Making Test Part B - Errors
Secondary
Olfactory Function
Beyond the preview
Go deeper on NCT01436045.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01436045.